martes, 19 de marzo de 2019

Sandoz "good by"...


Novartis is transforming its generics unit, a process that now includes a change in leadership. On Thursday, the Swiss pharma giant announced Sandoz CEO Richard Francis will step down at the end of the month. 

Francis took the helm of Sandoz in 2014, following 13 years at Biogen where he held various executive roles. Francesco Balestrieri, head of Sandoz's European division, will serve as interim CEO. 

In a statement, Francis pointed to the evolution taking place at Sandoz as the main reason for his departure. "I realize that this is a multi-year journey which I cannot commit to and therefore have decided that now is the right time to step down," he said. (Más)

No hay comentarios: